Sanofi’s experimental drug tolebrutinib has shown positive results in a Phase 3 study for non-relapsing secondary progressive multiple sclerosis (nrSPMS), demonstrating a delay in disability progression compared to placebo. While previous studies on relapsing forms of MS did not meet the primary endpoint, the latest findings suggest tolebrutinib’s potential as a treatment option for secondary progressive MS.
Sanofi’s experimental drug, tolebrutinib, has shown positive results in delaying disability progression in patients with non-relapsing secondary progressive multiple sclerosis (nrSPMS). While the drug did not meet the primary endpoint in relapsing forms of MS, secondary data showed a significant delay in disability worsening. However, concerns regarding potential liver damage and effectiveness remain, impacting the drug’s revenue prospects.
